Emerging Minds Journal for Student Research
January 25, 2026
Rishika Scott, James Smith
Treatment-resistant depression (TRD) has been well-researched within scientific literature, although the therapeutic value of psilocybin is not fully understood. The aim of this systematic review is to determine a stable and effective dosage unit to inform health professionals of the benefits of psilocybin, using peer-reviewed literature and meta-analysis. The review will also compare selective...
Neuroscience & Biobehavioral Reviews
January 24, 2026
Omer A. Syed, Benjamin Tsang, Sean M. Nestor et al.
Psilocybin-assisted therapy (PAT) is an emerging intervention for depression. Though several clinical trials report promising results for PAT in treating depression, there remains a need for consensus on optimal methodologies and standardization of PAT protocols. The objective of this review was to assess the efficacy of PAT in treating depressive symptoms and to systematically examine the...
Zenodo (CERN European Organization for Nuclear Research)
January 22, 2026
Psilocybin therapy shows potential benefits for mental health conditions such as depression and substance use disorders, though further research is needed to confirm long-term safety and efficacy.
Neuropharmacology
January 21, 2026
Ana Domi, Erika Lucente, Davide Cadeddu et al.
1 citation
Psilocybin is a naturally occurring psychedelic compound with potential antidepressant effects. Although it has long been used by humans, primarily for recreational purposes, the molecular mechanisms underlying its actions remain incompletely understood. Here, we examined the acute effects of psilocin, the active metabolite of psilocybin, on excitatory neurotransmission in the prefrontal cortex...
Nan fang yi ke da xue xue bao = Journal of Southern Medical University
January 20, 2026
Ke Xia, Tianming Gao
Depression is a complex and globally prevalent mental disorder, for which conventional antidepressant medications face limitations such as delayed onset and insufficient efficacy. Classic psychedelics, most notably psilocybin, have recently emerged as promising candidates for treatment of depression and demonstrated rapid, robust, and sustained antidepressant effects in controlled clinical...
Psychedelic Medicine
January 18, 2026
Anthony L. Back, Bonnie A. Mcgregor, Leslie Lazar Thorn et al.
1 citation
Background: Psilocybin is a promising therapy for cancer-related distress, but existing individual treatment models are resource intensive. In this study, we designed and tested a group model of psilocybin therapy for people with metastatic cancer and cancer-related anxiety and depression. Method: Eligibility criteria included metastatic cancer, moderate-to-severe symptoms of anxiety or...
January 15, 2026
Benjamin Kelmendi, Thomas G. Adams, Terence H. W. Ching et al.
preprint
Background: Obsessive-compulsive disorder (OCD) affects 2-3% of the population worldwide. 40-60% of patients do not respond to first-line interventions. We evaluated the efficacy and safety of a single dose of psilocybin in patients with treatment-resistant OCD.Methods: In this phase 2, randomized, double-blind trial, we randomly assigned 28 adults with treatment-resistant OCD to receive a...
2026
Irina Dell'Orto
Background: Psilocybin-assisted therapy (PAT) has demonstrated rapid and substantial antidepressant effects in phase 2 RCTs (Davis et al., 2021; Carhart-Harris et al., 2021), and phase 3 trials are now active (Usona uAspire, NCT06308653). However, three critical gaps remain unresolved in 2025: (1) the durability of effects beyond 12 months has not been established in a controlled design; (2)...
2026
Canyon Akromis, Lorraine Li, Kwon Mok Ko et al.
This project is a secondary analysis of data from Psilocybin in Depression Resistant to Standard Treatments (PsiDeR) study, a phase II, randomised, placebo-controlled clinical trial where participants with treatment resistant depression received either 25 mg of psilocybin or a placebo alongside psychotherapy. This research seeks to determine whether the therapeutic alliance, measured by the...
Advances in experimental medicine and biology
2026
Berend Olivier, Jocelien D A Olivier
Major depressive disorder (MDD), including treatment-resistant depression (TRD), is a highly prevalent psychiatric disorder. MDD is associated with severe suffering, burden and large economical costs. Although various conventional antidepressant treatments are available, a large portion of depressed people does not or not adequately respond to the first-line treatments (mostly SSRIs and SNRIs)...